Thromb Haemost 2018; 118(02): 351-361
DOI: 10.1160/TH17-04-0302
Cellular Haemostasis and Platelets
Schattauer GmbH Stuttgart

Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin

Mariam Ebrahim
,
Janina Jamasbi
,
Kristin Adler
,
Remco T. A. Megens
,
Yacine M'Bengue
,
Xavier Blanchet
,
Kerstin Uhland
,
Martin Ungerer
,
Richard Brandl
,
Christian Weber
,
Natalie Elia
,
Reinhard Lorenz
,
Götz Münch
,
Wolfgang Siess
Further Information

Publication History

29 April 2017

17 September 2017

Publication Date:
29 January 2018 (online)

Abstract

Platelet glycoprotein VI (GPVI) acts as a decisive collagen receptor in atherothrombosis. Besides collagen, injured atherosclerotic plaques expose tissue factor (TF) that triggers fibrin formation. Two recent studies reported that platelet GPVI also functions as fibrin receptor, which would importantly widen the mode of action of GPVI-targeted antithrombotic drugs. We studied the binding of two GPVI fusion proteins to fibrin under static and arterial flow conditions. Fibrin was prepared from purified fibrinogen or generated more physiologically from endogenous fibrinogen by coagulating plasma with thrombin. Fibrin formation was also triggered by exposing TF-coated surfaces or human atherosclerotic plaque slices to arterially flowing blood. By binding studies and advanced optical imaging, we found that recombinant dimeric GPVI-Fc fusion proteins with Fc from either IgG1 (GPVI-Fc1) or IgG2 (GPVI-Fc2) bound to collagen fibres, but neither to fibrin prepared from purified fibrinogen obtained from three suppliers, nor to physiological fibrin formed by thrombin in plasma or triggered by exposing TF or atherosclerotic plaque slices to arterially flowing blood. Our findings do not support a role of dimeric platelet GPVI as receptor for fibrin. This is important for the understanding of plaque-triggered platelet thrombus formation and is clinically relevant for future GPVI-targeting therapies with recombinant GPVI-Fc and anti-GPVI antibodies.

Financial Support

The study was supported by grants from the Bayerische Forschungsstiftung (AZ 1145–14), the Deutsche Forschungsgemeinschaft (SFB1123/Z01 and B08) and the August-Lenz foundation.


The review process for this paper was fully handled by Gregory Y. H. Lip, Editor in Chief.


 
  • References

  • 1 Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 2014; 276 (06) 618-632
  • 2 Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46 (06) 937-954
  • 3 Reininger AJ, Bernlochner I, Penz SM. , et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010; 55 (11) 1147-1158
  • 4 Penz S, Reininger AJ, Brandl R. , et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005; 19 (08) 898-909
  • 5 van Zanten GH, de Graaf S, Slootweg PJ. , et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93 (02) 615-632
  • 6 Badimon JJ, Lettino M, Toschi V. , et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99 (14) 1780-1787
  • 7 Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood 1990; 76 (02) 345-353
  • 8 Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11 (01) 2-16
  • 9 Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor?. Blood 2003; 102 (02) 449-461
  • 10 Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 1999; 274 (41) 29019-29024
  • 11 Jandrot-Perrus M, Busfield S, Lagrue AH. , et al. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000; 96 (05) 1798-1807
  • 12 Jung SM, Moroi M, Soejima K. , et al. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem 2012; 287 (35) 30000-30013
  • 13 Jung SM, Tsuji K, Moroi M. Glycoprotein (GP) VI dimer as a major collagen-binding site of native platelets: direct evidence obtained with dimeric GPVI-specific Fabs. J Thromb Haemost 2009; 7 (08) 1347-1355
  • 14 Loyau S, Dumont B, Ollivier V. , et al. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol 2012; 32 (03) 778-785
  • 15 Schulz C, Penz S, Hoffmann C. , et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008; 103 (04) 356-367
  • 16 Jamasbi J, Megens RT, Bianchini M. , et al. Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-Fc and anti-GPVI antibodies: Functional and imaging studies. J Am Coll Cardiol 2015; 65 (22) 2404-2415
  • 17 Auger JM, Kuijpers MJ, Senis YA, Watson SP, Heemskerk JW. Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB J 2005; 19 (07) 825-827
  • 18 Herr AB, Farndale RW. Structural insights into the interactions between platelet receptors and fibrillar collagen. J Biol Chem 2009; 284 (30) 19781-19785
  • 19 Kuijpers MJ, Schulte V, Bergmeier W. , et al. Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J 2003; 17 (06) 685-687
  • 20 Grüner S, Prostredna M, Aktas B. , et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Circulation 2004; 110 (18) 2946-2951
  • 21 Inoue O, Suzuki-Inoue K, McCarty OJ. , et al. Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. Blood 2006; 107 (04) 1405-1412
  • 22 Bültmann A, Li Z, Wagner S. , et al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin. J Mol Cell Cardiol 2010; 49 (03) 532-542
  • 23 Schönberger T, Ziegler M, Borst O. , et al. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. Am J Physiol Cell Physiol 2012; 303 (07) C757-C766
  • 24 Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001; 101 (05) 395-404
  • 25 Mammadova-Bach E, Ollivier V, Loyau S. , et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 2015; 126 (05) 683-691
  • 26 Alshehri OM, Hughes CE, Montague S. , et al. Fibrin activates GPVI in human and mouse platelets. Blood 2015; 126 (13) 1601-1608
  • 27 Ungerer M, Li Z, Baumgartner C. , et al. The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLoS One 2013; 8 (08) e71193
  • 28 Ungerer M, Rosport K, Bültmann A. , et al. Novel antiplatelet drug Revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011; 123 (17) 1891-1899
  • 29 Kleiman NS, Kolandaivelu K. Expanding the roster: developing new inhibitors of intravascular thrombosis. J Am Coll Cardiol 2015; 65 (22) 2416-2419
  • 30 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (08) 1894-1904
  • 31 Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011; 31 (03) 494-499
  • 32 Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84 (02) 289-297
  • 33 Brandl R, Richter T, Haug K, Wilhelm MG, Maurer PC, Nathrath W. Topographic analysis of proliferative activity in carotid endarterectomy specimens by immunocytochemical detection of the cell cycle-related antigen Ki-67. Circulation 1997; 96 (10) 3360-3368
  • 34 Jamasbi J, Megens RT, Bianchini M. , et al. Cross-linking GPVI-Fc by anti-Fc antibodies potentiates its inhibition of atherosclerotic plaque- and collagen-induced platelet activation. JACC Basic Transl Sci 2016; 1 (131) 142-13
  • 35 Elia N, Ott C, Lippincott-Schwartz J. Incisive imaging and computation for cellular mysteries: lessons from abscission. Cell 2013; 155 (06) 1220-1231
  • 36 Heintzmann R, Cremer C. Axial tomographic confocal fluorescence microscopy. J Microsc 2002; 206 (Pt 1): 7-23